Long non-coding RNA TMEM51-AS1 inhibits colorectal cancer progression

被引：0

作者：

Dongping Wu ^{[1
]}

Qing Xia ^{[2
]}

Xinming Su ^{[3
]}

Yunan Mao ^{[3
]}

Jiwei Mao ^{[4
]}

Qiannan Ding ^{[3
]}

Jianjiang Liu ^{[1
]}

Wangyan Zhong ^{[5
]}

Xiaoyu Zhang ^{[1
]}

Hanbing Li ^{[1
]}

Shiwei Duan ^{[1
]}

机构：

[1] Shaoxing People’s Hospital,Department of Radiation Oncology

[2] Zhejiang University of Technology,College of Pharmacy

[3] Hangzhou City University,Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine

[4] Hangzhou City University,Department of Clinical Medicine

[5] Shaoxing People’s Hospital,Medical Research Center

来源：

Discover Oncology | / 16卷 / 1期

关键词：

LncRNA; TMEM51-AS1; CRC; Expression; Downregulation; Progression;

D O I：

10.1007/s12672-025-02676-z

中图分类号：

学科分类号：

摘要：

Colorectal cancer (CRC) is the third most common cause of death worldwide and has high mortality and a poor prognosis. Long non-coding RNAs (lncRNAs) are non-coding RNAs longer than 200 nucleotides that play roles in cancer through multiple mechanisms. TMEM51-AS1 is a newly discovered 40,650 bp lncRNA. Our results showed that TMEM51-AS1 expression was significantly downregulated in CRC tissues (fold change = 0.74, P < 0.0001). This finding was confirmed in 20 pairs of CRC carcinoma and paracancerous tissues (fold change = 0.5, P < 0.001). Additionally, TMEM51-AS1 expression was found to be significantly reduced in CRC cell lines compared to normal human intestinal epithelial cells (P < 0.001). Bioinformatic analysis revealed that TMEM51-AS1 expression was associated with immune escape, RNA methylation, and DNA damage and repair. TMEM51-AS1 may also activate energy metabolism pathways to participate in cancer development. Drug sensitivity analysis confirmed that several drugs are more effective in CRC patients with high expression of TMEM51-AS1. In conclusion, our study demonstrates that TMEM51-AS1 can suppress the progression of CRC.

引用